| Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. | |
| | |
MedLine Citation:
|
PMID: 17622759 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: It is widely accepted that antiplatelet therapy is effective for secondary prevention of atherosclerotic vascular diseases. We performed a double-blind, controlled clinical-pharmacological study to investigate the antiplatelet efficacy of sarpogrelate, a selective 5-hydroxytryptamine (5-HT(2A)) receptor antagonist, in patients with ischemic stroke, using a new assessment system employing combinations of 5-HT and epinephrine as agonists. METHODS: Forty-seven patients with ischemic stroke were randomly assigned to three groups: 15 patients received 25 mg sarpogrelate (group L), 16 patients received 50 mg (group M), and 15 patients received 100 mg (group H) orally, three times daily for 7 days. The effect was expressed as maximum intensity of platelet aggregation on the last day of medication. Two combinations of agonists, 0.5 micromol/l 5-HT plus 3 micromol/l epinephrine, and 1 micromol/l 5-HT plus 3 micromol/l epinephrine, were used to induce platelet aggregation. RESULTS: With both combinations of agonists, sarpogrelate treatment inhibited platelet aggregation dose-dependently (p < 0.025, Jonckheere test). In multiple-group comparison, the effect in group H was greater than that in group L or M (p < 0.025, Wilcoxon rank-sum test). CONCLUSION: Sarpogrelate treatment inhibited platelet aggregation dose-dependently in patients with ischemic stroke, as judged by a new assessment system employing combinations of 5-HT and epinephrine as agonists. |
| | |
Authors:
|
Shinichiro Uchiyama; Yukio Ozaki; Kaneo Satoh; Kazuoki Kondo; Katsuya Nishimaru |
Related Documents
:
|
18678119 - Is fresh frozen plasma effective for thrombocytopenia in adults with dengue fever? a pr... 8173019 - Platelet membrane fluidity and plasma malondialdehyde levels in alzheimer's demented pa... 18448989 - Platelet gel supplementation in long bone nonunions treated by external fixation. 19192749 - Postoperative surgical chest and leg incision sites using platelet gel: a retrospective... 11487379 - A single (investigator)-blind randomised control trial comparing the effects of quinapr... 6870999 - Protective effects of dietary calcium and magnesium on platelet function and atheroscle... 3787559 - Defective contact activation of platelets from dogs with basset hound hereditary thromb... 22746279 - A method for the automated processing and analysis of images of ulvwf-platelet strings. 16194939 - Does binocular disparity or familiar size information override effects of relative size... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2007-07-04 |
Journal Detail:
|
Title: Cerebrovascular diseases (Basel, Switzerland) Volume: 24 ISSN: 1015-9770 ISO Abbreviation: Cerebrovasc. Dis. Publication Date: 2007 |
Date Detail:
|
Created Date: 2007-08-23 Completed Date: 2007-10-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9100851 Medline TA: Cerebrovasc Dis Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 264-70 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. suchiyam@nij.twmu.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Aged Blood Platelets / drug effects*, metabolism Brain Ischemia / blood, complications*, drug therapy Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Epinephrine / metabolism Female Humans Japan Male Middle Aged Platelet Aggregation / drug effects* Platelet Aggregation Inhibitors / administration & dosage, adverse effects, therapeutic use* Platelet Function Tests / methods Receptor, Serotonin, 5-HT2A / antagonists & inhibitors*, metabolism Serotonin / metabolism Serotonin Antagonists / administration & dosage, adverse effects, therapeutic use* Stroke / blood, drug therapy*, etiology Succinates / administration & dosage, adverse effects, therapeutic use* Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 0/Receptor, Serotonin, 5-HT2A; 0/Serotonin Antagonists; 0/Succinates; 50-67-9/Serotonin; 51-43-4/Epinephrine; 86819-20-7/sarpogrelate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of c...
Next Document: The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk ...